BioSpace News Archive

Calliditas Therapeutics AB announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon delayed release capsules) versus placebo in patients with primary IgA nephropathy.

Horizon Therapeutics plc announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease patients with DON, the majority of whom had not previously responded to other treatments.

Everest Medicines, a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines in Greater China and other parts of Asia, would like to announce that it considers its exposure to any liquidity concerns at Silicon Valley Bank to be immaterial.

HUTCHMED Limited confirms that it does not have any exposure to Silicon Valley Bank or Silicon Valley Bank UK Limited.

Agenus announced that it has cancelled its conference call on Monday, March 13th to discuss its minority cash holdings at Silicon Valley Bank in light of the government’s SVB deposit access announcement.